Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, December 1999, p. 2930-2938, Vol. 43, No. 12
Department of Botany, University of Toronto,
Mississauga, Ontario, Canada L5L 1C61;
Mycology Laboratory, Ontario Ministry of Health,
Laboratories Branch, Toronto, Ontario, Canada M5W
1R52; Department of Laboratory
Medicine and Pathobiology, University of Toronto, Toronto, Ontario,
Canada M5G 1L53; Department of
Medicine, Division of Infectious Disease, The Toronto Hospital,
University of Toronto, Toronto, Ontario, Canada M5G
2C44; Department of Pediatric
Laboratory Medicine
Received 18 May 1999/Returned for modification 17 August
1999/Accepted 1 October 1999
If variation in azole resistance is due to inherent differences in
strains of Candida albicans, as a predominantly clonal organism, then correlation between multilocus genotypes and drug resistance would be expected. A sample of 81 clinical isolates from
patients infected with human immunodeficiency virus in Toronto, Canada,
plus 3 reference isolates were genotyped at 16 loci, distributed on all
linkage groups, by means of oligonucleotide hybridizations specific for
each of the alleles at each locus. These multilocus genotypes were
significantly correlated with DNA fingerprints obtained with the
species-specific probe 27A, indicating widespread linkage
disequilibrium in the genome. There were 64 multilocus diploid
genotypes and 77 DNA fingerprint types delineated in this sample.
Neither the multilocus genotyping nor DNA fingerprinting alone
identified all of the 81 types identified by the combination of these
two methods. Multilocus genotypes were not predictive of fluconazole
resistance, suggesting that resistance is gained or lost too quickly to
be predicted by linkage with neutral markers.
The deployment of antimicrobial
agents in medicine and agriculture is nearly always followed by the
evolution of resistance to these agents in the pathogen
(23). In fungal pathogens, the dramatic increase in the
incidence of opportunistic infections in recent years has been
accompanied by an equally dramatic increase in resistance by the
pathogen to the limited number of antifungal drugs available. For
example, the yeast Candida albicans and related species
cause serious illness in immunocompromised patients, such as those who
are positive for human immunodeficiency virus (HIV). Although the
introduction of azole drugs, especially fluconazole, has greatly
facilitated the treatment of infections caused by Candida,
the emergence of resistance in this yeast may have severely reduced the
effectiveness of azoles (12, 16, 26).
Our interest is in the evolutionary mechanisms of emergence and spread
of resistance to antifungal agents in the pathogenic yeast C. albicans. In this study, we compared resistance to the azole drugs
fluconazole, ketoconazole, and itraconazole with multilocus genotypes
based on nucleotide site polymorphisms in a sample of 89 isolates of
Candida from oral mucosa in a group of HIV-infected patients
in Toronto, Canada. Linkage disequilibrium among neutral genetic
markers in C. albicans is well documented (5, 15, 24,
25), even where there is no genetic differentiation among geographically diverse samples of C. albicans (10, 28,
29). Because of the linkage disequilibrium, indicative of a
primarily clonal system, we reasoned that variation in multilocus
genotypes based on neutral polymorphisms should be positively
correlated with variation in drug resistance, but only if the
resistance phenotype is stable enough for such an association to exist.
In the actual comparison, we found that variation among multilocus genotypes was not predictive of variation in the level of fluconazole resistance. This suggests that fluconazole resistance in populations is
labile; resistance is either gained or lost too quickly to be predicted
by linkage with neutral markers in this population sample.
In order to compare azole resistance and multilocus genotypes, we
developed a new genotyping system based on an assay of nucleotide polymorphisms distributed on all chromosomes. Several methods for
genotyping strains of C. albicans have been used to describe populations of this fungus (reviewed by Pujol et al.
[14]). Our method uses allele-specific oligonucleotide
probes in Southern hybridizations with PCR-amplified DNA regions. The
system clearly distinguishes heterozygotes from homozygotes at each
polymorphic site, resulting in an unambiguous multilocus genotype for
each isolate tested. In the process of genotyping, we also found eight highly atypical isolates, seven of which were later identified as
C. dubliniensis and one of which was identified as C. tropicalis; the remaining sample consisted of 81 clinical
isolates of C. albicans.
To test the discriminatory power of the genotyping system, DNA
fingerprints were obtained with the commonly used species-specific probe 27A. There are approximately 10 copies of the 27A sequence dispersed throughout the genome. DNA polymorphisms are produced at high
rates, largely due to internal changes in members of this gene family
(22). These polymorphisms have been widely used in studies
of C. albicans. The number of allelic differences among multilocus genotypes was positively correlated with the number of
differences in the hybridizing fragments present in DNA fingerprints; this indicated widespread linkage disequilibrium in this population of
C. albicans and validated our rationale for comparing
genotypes and drug resistance.
The objective of this population-genetic study was to determine if
azole resistance can be predicted by multilocus genotype in a sample of
C. albicans isolates from HIV-infected patients. This was
done by comparing two DNA typing methods and examining the relationship
between DNA typing markers and azole resistance.
Strains of Candida.
Of the 89 isolates initially
identified as C. albicans obtained from oral swabs from
HIV-infected patients (Table 1), 22 isolates were from patients attending the Immunodeficiency Clinic at
the Hospital for Sick Children (HSC) and 67 isolates were from patients
attending the Toronto Hospital Immunodeficiency Clinic. We selected
this geographically restricted sample because the patients from which
this sample was obtained are more likely to be infected by the same
pool of strains of this fungus jointly sharing in the processes of
genetic drift and selection than would patients from different
locations.
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Multilocus Genotypes and DNA Fingerprints Do Not
Predict Variation in Azole Resistance among Clinical Isolates of
Candida albicans
Microbiology, The Hospital for Sick Children,
Toronto, Ontario, Canada M5G 1X85
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
TABLE 1.
Azole resistance levels
70°C.
Species identification of the Candida isolates was by
standard methods at HSC and the Toronto Public Health Laboratory
(TPHL). Oral swabs were streaked on inhibitory mold agar
(17) with 5 µg of ciprofloxacin per ml. Isolates that grew
at 35°C within 7 days were subcultured to Sabouraud's
peptone-glucose agar at HSC. Isolates were tested for germ tube
formation (13) in rabbit serum held at 35°C for 3 h;
isolates positive for germ tubes were identified as C. albicans. The remaining isolates were grown on corn meal-Tween 80 agar (13) for morphological examination and were tested with
commercial assimilation kits (API 20C; bioMérieux, Inc., St.
Louis, Mo.) for evaluation of physiological characters. Cultures not
identified to a high confidence level with these techniques were
referred to TPHL. At TPHL, isolates were grown on 2% oxgall medium
(4); isolates that formed characteristic chlamydospores at
28°C after 48 h were identified as C. albicans sensu
lato (inclusive of Candida stellatoidea and Candida
dubliniensis). The remaining isolates were identified by reference
techniques, including Wickerham broth fermentation and auxanographic
assimilation of carbon and nitrogen substrates, the Christensen urease
test, and a test for growth at 37°C (3, 7, 8, 13). These reference techniques facilitate identification of atypical isolates of
C. albicans sensu lato that fail to produce germ tubes
and/or chlamydospores. Subsequently, C. dubliniensis
isolates were distinguished from C. albicans sensu stricto
by poor or no growth at 42°C and no growth at 45°C within 72 h
on Sabouraud's peptone-glucose agar (6).
PCR amplification.
PCR mixtures (20 µl) contained 0.5 µM
each primer, 200 µM deoxynucleoside triphosphates, 1× PCR buffer II
with 2 mM MgCl2 (Perkin-Elmer, Norwalk, Conn.), 0.5 U of
AmpliTaq DNA polymerase (Perkin-Elmer), and 10 µl of a 100-fold
dilution of genomic DNA prepared by the method of Scherer and Stevens
(21). Amplifications were carried out in a Perkin-Elmer
GeneAmp System 9600 thermocycler programmed for an initial denaturation
at 95°C for 8 min, followed by 35 cycles of denaturation at 95°C,
primer annealing at 50 to 58°C (Table
2), and extension at 72°C for 20, 30, and 60 s, respectively, with a 5-min extension at
72°C on the final cycle.
|
SSCP analysis.
Strains were screened for sequence-level
polymorphisms by using single-strand conformation polymorphisms
(SSCPs). Each primer (0.5 µM) was end-labeled with
[
-33P]ATP (60 fmol, 3,000 Ci/mmol; DuPont-NEN,
Markham, Ontario, Canada) and polynucleotide kinase (0.1 U; Gibco BRL,
Burlington, Ontario, Canada) at 37°C for 30 min. PCR analyses were
performed as described above except that each end-labeled primer was
added to all other reaction components to a final concentration of 0.5 µM in a volume of 12 µl. After cycling was complete, 4 µl of stop
solution (95% formamide, 10 mM EDTA [pH 8.0], 0.1% bromophenol
blue, 0.1% xylene cyanol) was added to the reaction mixtures. Reaction
mixtures were heat denatured and applied to 6% nondenaturing
polyacrylamide gels with low cross-linking (2% bisacrylamide) in 0.5×
Tris-borate-EDTA buffer, with and without 7% glycerol. Electrophoresis
was carried out at 150 V for 19 h for standard gels and 30 h
for gels containing glycerol. Gels were transferred to filter paper,
dried for 2 h at 80°C, and exposed to X-ray film (BIOMAX MR
Kodak film) for 16 h at room temperature.
DNA sequencing.
DNAs of up to three representatives of each
putative allelic class identified by SSCPs were sequenced. PCR products
were purified by using the Geneclean II kit (Bio 101, La Jolla, Calif.)
in accordance with the manufacturer's instructions and then eluted in
10 µl of sterile distilled water. One microliter of a purified PCR
product was sequenced directly by using the chain-terminating,
dideoxynucleotide double-stranded DNA cycle sequencing system (Gibco
BRL) and [
-33P]ATP (3,000 Ci/mmol; DuPont-NEN)
according to the manufacturer's protocol. Sequencing reactions were
subjected to electrophoresis on 6% polyacrylamide gels under
denaturing conditions (SequaGel XR; National Diagnostics, Atlanta,
Ga.).
Oligonucleotide hybridization.
Southern blots of
PCR-amplified regions were prepared by standard procedures
(18). Allele-specific oligonucleotides were end-labeled with
[
-32P]ATP (3,000 Ci/mmol; DuPont-NEN) and hybridized
for 2 h to the Southern blots within 5°C of the midpoint
temperature of the probe (Table 2) according to the protocol of Saville
et al. (19). Three washes of 20 s each were done at the
same temperature as the hybridization. The blots were then exposed to
X-ray film at room temperature for 1 h.
Fingerprinting.
A 10-µl sample of DNA was digested with 10 U of EcoRI for 4 h at 37°C, and digestion was stopped
by heating to 65°C for 10 min. Electrophoresis was carried out at 45 V for 22 h in 1% agarose gels in 1× Tris-acetate-EDTA buffer.
Southern blotting in 10× SSC (1× SSC is 0.15 M NaCl plus 0.015 M
sodium citrate) was by standard methods (18). Each blot was
hybridized with the species-specific probe 27A in pBR322 labeled by
nick translation with the Nick Translation System (Gibco BRL) and
[
-32P]dCTP (3,000 Ci/mmol; DuPont-NEN) according to
the manufacturer's instructions. For each DNA fingerprint, each of 42 distinct DNA fragment size classes was scored as present or absent;
genotypes were not inferred. Additional DNA fragments that hybridized
weakly to probe 27A were not scored.
Susceptibility testing.
The susceptibilities of each strain
to fluconazole were determined by the broth microdilution method using
the National Committee for Clinical Laboratory Standards (M27-A)
protocol (11). Fluconazole, supplied as a powder (Pfizer
Inc., New York, N.Y.), was reconstituted in sterile distilled water to
a concentration of 5,120 µg/ml and stored in aliquots at
70°C.
Susceptibilities of each strain to fluconazole, ketoconazole, and
itraconazole were also determined at HSC by use of the same procedure.
Distance analysis. For all statistical analyses, distances were defined as the minimum number of steps required for the transition between two genotypes, where each step represented a genetic change, either (i) the mutation of one allele to another or (ii) the loss of an allele in a heterozygote as the result of mitotic crossing over or gene conversion. For example, the distance between genotype CC and CT at a given site was recorded as one step, and the distance between CC and TT was recorded as two steps. The total distance between two multilocus genotypes was the sum of the distances for all 16 sites, with a maximum possible of 32 steps. For the DNA fingerprints, the distance between the presence and the absence of a given band was recorded as one step for a possible maximum of 42 steps. The MIC data were coded with a character from 0 to 9 on an exponential scale. For example, the distance between MICs of 0.125 and 0.5 µg/ml was two steps, and the distance between MICs of 0.125 and 64 µg/ml was nine steps. PAUP version 4.0b2 for Macintosh (D. L. Swofford, Smithsonian Institution) was used to calculate matrices of distances. Correspondence analysis was done as described by Legendre and Legendre (9).
| |
RESULTS |
|---|
|
|
|---|
Genotyping method.
Each of the 16 regions was amplified (Table
2) and examined for SSCPs under two different conditions. Putative
alleles were identified on the basis of electrophoretic mobility. These
alleles occurred in both homozygotes and heterozygotes. Up to three
representatives of each putative allele were sequenced, and polymorphic
nucleotide sites were identified (Table
3). For 16 sites that were polymorphic in
the majority of isolates, allele-specific, oligonucleotide hybridization probes were designed (Table 2). In most cases, these
probes contained a site of potential mismatch flanked by 7 to 8 bases.
Each hybridization clearly indicated the presence or absence of an
allele in an amplicon. Also, the intensity of the hybridization signal
indicated whether an allele was present in (i) all of the molecules of
an amplicon, as in a homozygote, or (ii) half of the molecules of an
amplicon, as in a heterozygote. No anomalies were encountered in the 84 isolates of C. albicans, and the genotypic data for these
isolates were complete.
|
Atypical strains.
In the entire sample of 92 isolates (89 clinical isolates plus 3 reference isolates), 8 isolates were highly
atypical (Table 4) relative to the
remaining 84 isolates identified as C. albicans. Seven of
these atypical isolates were later identified at TPHL as C. dubliniensis (T10, T12, T43, T44, T60, T74, and T127), and one was
identified as C. tropicalis (T93). In these atypical
isolates, some DNA regions amplified and hybridized to the
allele-specific probes designed for the 84 isolates of C. albicans, while other regions either contained large numbers of
sites with fixed differences relative to the C. albicans
sequences or failed to amplify.
|
Multilocus genotypes of C. albicans. Among the 84 isolates of C. albicans (81 isolates from patients plus 3 reference isolates), there were 64 multilocus diploid genotypes. Genotype counts at eight of the loci were consistent with Hardy-Weinberg expectation, while counts at eight loci deviated significantly from Hardy-Weinberg expectation (Table 3).
Variation among multilocus genotypes is represented by the ordination plot (9) in Fig. 1, in which the x-axis explains 26.7% of the variation and the y-axis explains 23.7% of the variation. The spatial positions of isolates in this plot are based on distances among their genotypes. In general, the closer two isolates are on the plot, the greater proportion of alleles they share. The spatial positions imply genotypic similarity but not relatedness (i.e., patterns of descent). This plot shows that isolates with very similar genotypes had a wide range of fluconazole MICs and, conversely, that isolates with the same MICs had diverse genotypes.
|
DNA fingerprints of C. albicans. To test the discriminatory power of the genotyping system, DNA fingerprints were obtained by using the repetitive probe 27A. The DNA fingerprints distinguished 77 phenotypes among the 84 isolates of C. albicans. Variation among the fingerprints is represented by the ordination plot in Fig. 2 in which the x-axis explains 12.4% of the variation and the y-axis explains 9.5% of the variation. As in Fig. 1, the plot in Fig. 2 is based on distances among DNA fingerprints. In general, the closer two isolates are on the plot, the greater proportion of DNA fragments they share. This plot shows that there was a wide range of fluconazole MICs for isolates with very similar DNA fingerprints and, conversely, that the MICs were the same for isolates with diverse DNA fingerprints.
|
Comparison of multilocus genotyping and DNA fingerprinting. The discriminatory powers of this multilocus genotyping system and DNA fingerprinting with probe 27A were compared. Two groups of isolates having identical multilocus genotypes also had identical DNA fingerprints (T50 and T56; T63, T65, and T68); each of these groups of isolates was recovered from a single patient (Table 1). In other cases, isolates with identical multilocus genotypes were found to have nonidentical DNA fingerprints and, conversely, isolates with identical fingerprints had nonidentical multilocus genotypes. The combination of multilocus genotypes and DNA fingerprints distinguished 81 unique types among the total of 84 strains.
The multilocus genotype and DNA fingerprint data were compared in an additional two ways. First, in order to test for general linkage disequilibrium in this sample of C. albicans, distances based on multilocus genotypes were compared with distances based on DNA fingerprints. In 3,486 pairwise comparisons of strains, the correlation was both positive and highly significant (r = 0.465, P < 0.001).Resistance to azole drugs.
The MICs of fluconazole ranged from
0.125 to 64 µg/ml, those of ketoconazole ranged from 0.03 to 16 µg/ml, and those of itraconazole ranged from 0.015 to 8 µg/ml for
the isolates of C. albicans (Table 1). The correlation of
resistance to fluconazole with resistance to ketoconazole and to
itraconazole was highly significant (r = 0.692, P < 0.001, and r = 0.593, P < 0.001,
respectively). Differences in fluconazole resistance were then compared
with distances based on (i) multilocus genotypes and (ii) DNA
fingerprints in the 3,486 pairwise comparisons among 84 strains of
C. albicans. The mean pairwise distance based on (i)
genotypes and (ii) fingerprints was compared to a distribution of mean
distances expected under the null hypothesis of no relationship between
MIC level and distance based on genotypes or fingerprints. For each MIC
class, 10,000 samples of the same number of distances were randomly
drawn, with replacement, from the set of all 3,486 pairwise distances
for the 84 isolates of C. albicans (Table
5). In most cases, the observed mean
distance was not significantly different from the null expectation; the
observed mean distance fell well within the range of mean distances in
the random samples. The only exceptions were groups MIC1 and MIC6, in
which the observed mean distances were significantly less than random
expectation.
|
| |
DISCUSSION |
|---|
|
|
|---|
This study was designed to determine if multilocus genotypes and DNA fingerprints predict variation in azole resistance in a sample of C. albicans isolates from HIV-infected patients as would be expected if variation in azole resistance was due to heritable differences among strains. Using a new genotyping system, we detected correlation between multilocus genotypes and 27A DNA fingerprints but did not detect correlation either between multilocus genotypes and azole resistance or between DNA fingerprints and azole resistance. Additionally, our genotyping method detected atypical isolates in the sample and has potential for identifying other Candida species.
The genotyping system developed here is based on polymorphisms in nucleotide sequences. The oligonucleotide hybridization assays are accurate, and the results are easily interpreted. Although all oligonucleotide hybridizations were done manually in this study, the same assays could readily be adapted for microchip technology (27) and automation. This would substantially increase throughput without loss of accuracy.
Clonal diversity in this sample was high, with 81 distinct types identified among 84 strains of C. albicans with the combination of multilocus genotypes and DNA fingerprints. This contrasts with other fungi also well known for clonal propagation (1, 2) in which certain genotypes were repeatedly recovered at much higher frequencies than any of the genotypes of C. albicans in this study. To test the resolving power of the new multilocus genotyping method, we compared its ability to distinguish clones of C. albicans with a reliable and widely used DNA fingerprinting method. Neither the multilocus genotyping nor DNA fingerprinting alone achieved "saturation" by identifying all of the 81 types identified by the combination of these two methods. Although fewer multilocus genotypes (64 genotypes) were identified in the sample of 84 strains of C. albicans than DNA fingerprint types (77 types), the number of loci assayed in the genotyping system could be increased without practical limit, resulting in enhanced discriminatory power.
In addition to distinguishing clones of this fungus, the multilocus genotyping system offers the possibility of phylogenetic analysis because both of the alleles present at each locus in this diploid genome are identified. Analysis of multilocus genotypes will be particularly useful in samples of highly related strains, such as in patients from which the fungus is sampled over time and in experimental populations in which, for example, loss of heterozygosity can be monitored over time. Assuming that C. albicans is predominantly clonal, it should also be possible to reconstruct a phylogeny of genotypes in larger samples of less-related strains such as the one sampled here. Reconstruction of the phylogeny of the 84 strains of C. albicans, however, was problematic for two reasons. First, the data set is large, including 84 strains (i.e., "taxa" in phylogenetic analyses), and it was not possible to find the shortest tree or trees from the set of all possible unrooted trees, regardless of the tree-building method. Second, there was a high level of homoplasy for individual characters in the neighbor-joining trees, which were slightly more parsimonious than the corresponding UPGMA trees. This homoplasy is not surprising; for example, a widespread ancestral genotype may lose heterozygosity in multiple, independent events of gene conversion or mitotic crossing over (20). Alternatively, genetic exchange and recombination can contribute to the homoplasy observed in trees that assume clonal evolution (25), although this interpretation may be less consistent with indications of linkage disequilibrium in this sample.
Because of the difficulty in representing relationships among the 84 genotypes of C. albicans as trees, we used instead an ordination plot to portray variation in multilocus genotypes (Fig. 1) and DNA fingerprints (Fig. 2); the advantage of this graphical method is that it does not force a bifurcating mode of evolution on the 84 isolates. In a comparison of multilocus genotypes and DNA fingerprints, the correlation of distances was positive and significant. This correlation is yet another indication of linkage disequilibrium in C. albicans and provides the framework for predicting other phenotypic traits from genotypic data based on neutral markers.
The primary objective of this study was to determine whether fluconazole resistance in a sample of isolates from a group of HIV-infected patients could be predicted by multilocus genotype. With linkage disequilibrium, multilocus genotypes would be expected to be correlated with levels of drug resistance, but only if the drug resistance phenotype is stable relative to the genetic markers. Existing variation in azole resistance among strains could be due either to (i) differences among strains in their history of exposure to the selective pressure imposed by the presence of the drug, (ii) differences in the inherent potential of strains to develop drug resistance, or (iii) both. The absence of any meaningful correlation between genotype and drug resistance implies that the wide variation in fluconazole resistance is not due to inherent differences in the ability to develop drug resistance. If this were the case, then a correlation between genotype and drug resistance would be expected, whether the history of exposure to the drug was uniform or not. Instead, fluconazole resistance was strikingly variable, even within the two putative clones. The significance of the correlation between DNA markers and azole resistance may well vary among samples. But to be sufficiently predictive to be useful, the correlation would have to be much larger than in the present sample.
The presence of atypical isolates in our sample was unanticipated but provided the opportunity to detect a multitude of nucleotide sequence differences in the 16 nuclear loci that distinguished isolates of C. albicans from those of other species (Table 4). Of the 89 isolates initially identified as C. albicans, seven were later re-identified by conventional means as C. dubliniensis and one was identified as C. tropicalis. One oligonucleotide probe for locus C12F10 and one for locus CHS2 could potentially serve as molecular probes for C. dubliniensis since they were species specific in this study. One oligonucleotide probe for locus HEX1 was specific for all the C. dubliniensis isolates with the exception of one, T43, which was divergent in numerous loci from both the remaining C. dubliniensis isolates and the C. albicans isolates.
Among the 84 isolates conclusively identified as C. albicans, the lack of correlation between DNA markers and azole
resistance suggests that azole resistance is either gained or lost too
frequently to be predicted by the more stable DNA markers. We are
currently testing this hypothesis by examining the development of drug
resistance and measuring its stability in replicated experimental
populations founded from the same initial genotype and exposed to
inhibitory drug concentrations over many generations. Another
explanation for the apparent lability of fluconazole resistance is that
a single strain repeatedly challenged with a drug may approach
different adaptive peaks by mutation in different sets of the genes
determining fluconazole resistance. These include the target gene
(ERG11), which encodes lanosterol 14
-demethylase, the
several efflux pumps capable of transporting fluconazole out of the
cell, including the superfamily of ATP binding cassette transporters
and the major facilitator superfamily, and any number of other genes
affecting the expression of any of the above. We are currently
examining all of these possibilities in experimental populations.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by a grant-in-aid from Pfizer Canada and Research Grants from the Natural Sciences and Engineering Research Council (NSERC) of Canada to L.M.K. and J.B.A. L.E.C. was supported by a NSERC Postgraduate Scholarship. Fungal susceptibility testing at HSC was supported by a grant from the MRC PMAC program to S.W. and S.R.
We thank P. T. Magee for furnishing reference isolates and the fingerprint probe and P. Peresneto for help with statistical analyses. We thank D. L. Swofford for the beta test version 4.0b2 of PAUP. We also thank M. Witkowska at TPHL for technical assistance.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Botany, University of Toronto at Mississauga, 3359 Mississauga Rd. North, Mississauga, Ontario, Canada L5L 1C6. Phone: (905) 828-5338. Fax: (905) 828-3792. E-mail: lcowen{at}credit.erin.utoronto.ca
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Anderson, J. B., and L. M. Kohn. 1995. Clonality in soilborne, plant-pathogenic fungi. Annu. Rev. Phytopathol. 33:369-391[Medline]. |
| 2. | Anderson, J. B., and L. M. Kohn. 1998. Genotyping, gene genealogies, and genomics bring fungal population genetics above ground. Trends Ecol. Evol. 13:444-449. |
| 3. | Barnett, J., R. Payne, and D. Yarrow. 1990. Yeasts: characteristics and identification, 2nd ed. Cambridge University Press, Cambridge, United Kingdom |
| 4. | Fischer, J., and J. Kane. 1968. Production of chlamydospores by Candida albicans cultivated on dilute oxgall agar. Mycopatholog. Mycol. Appl. 35:223-229. |
| 5. |
Gräser, Y.,
M. Volovsek,
J. Arrington,
G. Schönian,
W. Presber,
T. G. Mitchell, and R. Vilgalys.
1996.
Molecular markers reveal that population structure of the human pathogen Candida albicans exhibits both clonality and recombination.
Proc. Natl. Acad. Sci. USA
93:12473-12477 |
| 6. |
Kirkpatrick, W.,
S. Revankar,
R. McAtee,
J. Lopez-Ribot,
A. Fothergill,
D. McCarthy,
S. Sanche,
R. Cantu,
M. Rinaldi, and T. Patterson.
1998.
Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar Candida screening and susceptibility testing of isolates.
J. Clin. Microbiol.
36:3007-3012 |
| 7. | Kreger-van Rij, N. 1984. The yeasts, a taxonomic study, 3rd ed. Elsevier, Amsterdam, The Netherlands |
| 8. | Kurtzman, C., and J. Fell. 1998. The yeasts, a taxonomic study, 4th ed. Elsevier, Amsterdam, The Netherlands |
| 9. | Legendre, P., and L. Legendre. 1998. Correspondence analysis, p. 451-476. In Numerical ecology, 2nd English ed. Elsevier, New York, N.Y |
| 10. | Lott, T. J., B. P. Holloway, D. A. Logan, R. Fundyga, and J. Arnold. 1999. Towards understanding the evolution of the human commensal yeast Candida albicans. Microbiology 145:1137-1143[Medline]. |
| 11. | National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, p. 1-29. National Committee for Clinical Laboratory Standards, Wayne, Pa |
| 12. |
Odds, F. C.
1993.
Resistance of yeasts to azole-derivative antifungals.
J. Antimicrob. Chemother.
31:463-471 |
| 13. | Pincus, D., and I. Salkin. 1988. Human infections caused by yeast-like fungi, p. 239-269. In B. Wentworth, M. Bartlett, B. Robinson, and I. Salkin (ed.), Diagnostic procedures for mycotic and parasitic infections, 7th ed. American Public Health Association, Washington, D.C. |
| 14. | Pujol, C., S. Joly, S. R. Lockhart, S. Noel, M. Tibayrenc, and D. R. Soll. 1997. Parity among the randomly amplified polymorphic DNA method, multilocus enzyme electrophoresis, and Southern blot hybridization with the moderately repetitive DNA probe Ca3 for fingerprinting Candida albicans. J. Clin. Microbiol. 35:2348-2358[Abstract]. |
| 15. |
Pujol, C.,
J. Reynes,
F. Renaud,
M. Raymond,
M. Tibayrenc,
F. J. Ayala,
F. Janbon,
M. Mallie, and J. M. Bastide.
1993.
The yeast Candida albicans has a clonal mode of reproduction in a population of infected human immunodeficiency virus-positive patients.
Proc. Natl. Acad. Sci. USA
90:9456-9459 |
| 16. | Rex, J. H., M. G. Rinaldi, and M. A. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39:1-8[Medline]. |
| 17. | Salkin, I. 1988. Media and stains for mycology, p. 379-411. In B. Wentworth, M. Bartlett, B. Robinson, and I. Salkin (ed.), Diagnostic procedures for mycotic and parasitic infections, 7th ed. American Public Health Association, Washington, D.C. |
| 18. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y |
| 19. |
Saville, B. J.,
Y. Kohli, and J. B. Anderson.
1998.
mtDNA recombination in a natural population.
Proc. Natl. Acad. Sci. USA
95:1331-1335 |
| 20. |
Scherer, S., and P. T. Magee.
1990.
Genetics of Candida albicans.
Microbiol. Rev.
54:226-241 |
| 21. |
Scherer, S., and D. A. Stevens.
1987.
Application of DNA typing methods to epidemiology and taxonomy of Candida species.
J. Clin. Microbiol.
25:675-679 |
| 22. |
Scherer, S., and D. A. Stevens.
1988.
A Candida albicans dispersed, repeated gene family and its epidemiologic applications.
Proc. Natl. Acad. Sci. USA
85:1452-1456 |
| 23. | Taylor, M., and R. Feyereisen. 1996. Molecular biology and evolution of resistance to toxicants. Mol. Biol. Evol. 13:719-734[Abstract]. |
| 24. | Tibayrenc, M. 1997. Are Candida albicans natural populations subdivided? Trends Microbiol. 5:253-254[Medline]. |
| 25. | Vilgalys, R., Y. Gräser, G. Schönian, and W. Presber. 1997. Response to Tibayrenc. Trends Microbiol. 5:254-257. |
| 26. |
White, T. C.,
K. A. Marr, and R. A. Bowden.
1998.
Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.
Clin. Microbiol. Rev.
11:382-402 |
| 27. |
Winzeler, E. A.,
D. R. Richards,
A. R. Conway,
A. L. Goldstein,
S. Kalman,
M. J. McCullough,
J. H. McCusker,
D. A. Stevens,
L. Wodicka,
D. J. Lockhart, and R. W. Davis.
1998.
Direct allelic variation scanning of the yeast genome.
Science
281:1194-1197 |
| 28. | Xu, J., T. G. Mitchell, and R. Vilgalys. 1999. PCR-restriction fragment length polymorphism (RFLP) analyses reveal both extensive clonality and local genetic differences in Candida albicans. Mol. Ecol. 8:59-73[Medline]. |
| 29. |
Xu, J.,
R. Vilgalys, and T. G. Mitchell.
1999.
Lack of genetic differentiation between two geographically diverse samples of Candida albicans isolated from patients infected with human immunodeficiency virus.
J. Bacteriol.
181:1369-1373 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |